Preclinical safety assessment of recombinant human GM-CSF in rhesus monkeys.
Robison
R L
RL
Department of Pathology and Experimental Pathology, Sandoz Pharmaceuticals Corporation, East Hanover, New Jersey 07936.
Myers
L A
LA
D000818:Animals; D001259:Ataxia / Q000139:chemically induced; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000473:pathology; D002452:Cell Count / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004487:Edema / Q000139:chemically induced; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000633:toxicity*; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D006965:Hyperplasia; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008253:Macaca mulatta; D008297:Male; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000633:toxicity*; D012700:Serositis / Q000139:chemically induced; D012871:Skin Diseases / Q000139:chemically induced; D015431:Weight Loss / Q000187:drug effects
D011993:Recombinant Fusion Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor